Michael Mingueneau
Vice President, Immunology Sail Biomedicines
Seminars
Thursday 26th March 2026
In Vivo Transient Programming of T Cells with Targeted Nanoparticles Encapsulating eRNA-encoded hCD19 CAR Achieves Deep Depletion of B cells in tissues and immune Reset
2:30 pm
- In vivo CAR-T cell engineering has the potential to transform the care of patients with autoimmune diseases by simplifying and broadening access to treatments with potential for cures
- Sail’s in vivo CAR-T drug candidate (DC) has been engineered and extensively optimized to achieve an optimal dose efficiency profile and ultimately therapeutic index in patients with autoimmune conditions. As a result, Sail’s in vivo CAR-T DC is able to achieve deep tissue depletion of B cells and effectively reset the B cell compartment at low dose levels
- Sail’s in vivo CAR-T DC has the potential to replace complex, costly, and genomeintegrative cell therapy products with an off-the-shelf and non-integrative IV injectable product that avoids the safety risks associated with lymphoablative conditioning
